Generalized tonic-clonic seizures (GTCS) are a common and severely debilitating seizure type. These seizures are associated with a high level of morbidity and mortality, with potentially serious complications, including head trauma, falls and fractures, aspiration pneumonia, and sudden unexpected death in epilepsy (SUDEP). Despite the severity of GTCS, considerable barriers exist that limit physicians’ ability to accurately diagnose this seizure type, initiate early treatment, recognize and manage treatment resistance, and improve patient adherence with treatment regimen and continuity of care.
Fortunately, many of these barriers are remediable through increased knowledge among neurologists and epileptologists. This program will include updates on the recently released International League Against Epilepsy classification of seizure types, American Academy of Neurology Practice Guideline on SUDEP, and recent advances in management of treatment-refractory GTCS, including updates on use of adjunctive therapies and cannabinoids.
Upon successful completion of this educational activity, participants should be better able to:
Gregory L. Krauss, MD
Professor of Neurology
The Johns Hopkins Hospital
Tracey A. Milligan, MD (Co-Course Director)
Vice Chair for Education
Department of Neurology
Harvard Medical School
Georgia D. Montouris, MD (Course Director)
Clinical Associate Professor of Neurology
Boston University School of Medicine
Director, Epilepsy Services
Boston Medical Center
Joseph I. Sirven, MD
Professor of Neurology
Director, Epilepsy Division
Michael C. Smith, MD
Director, Rush Epilepsy Center
Professor of Neurological Sciences
Rush University Medical Center
|7:30 am - 8:00 am||Registration and Complimentary Breakfast|
|8:00 am - 8:10 am||Welcome and Opening Remarks|
|8:10 am - 8:30 am||
Impact and Burden of Epilepsy
|8:30 am - 9:00 am||
|9:00 am - 9:10 am||Break|
|9:10 am - 10:00 am||
Optimizing the Management of Generalized Tonic-Clonic Seizures (GTCS)
|10:00 am - 10:30 am||
Special Considerations in Lennox-Gastaut Syndrome
|10:30 am - 10:40 am||Break|
|10:40 am - 11:00 am||Strategies to Improve Medication Adherence|
|11:00 am - 11:50 am||
Interactive Case Studies
|11:50 am - 12:00 pm||Closing Remarks|
This program is designed specifically for epileptologists, neurologists, neurology fellows, and other healthcare professionals who provide care for patients with epilepsy.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem Health. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Boston University School of Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To request reasonable accommodations for a disability, please contact Pietra Kilcullen, firstname.lastname@example.org, in writing, at least 2 weeks prior to the program date.
It is the policy of Boston University School of Medicine Department of Continuing Medical Education, that faculty disclose to program participants any real or apparent conflict of interest. In addition, the faculty is asked to disclose any discussion pertaining to the unapproved use of pharmaceuticals and devices. Complete disclosure information will be available on site in the printed course materials.
Dr. Krauss: consultant: Eisai Laboratories; research grant support: SK Life Science, Inc., UCB, Inc., and Upsher-Smith Laboratories, LLC. Dr. Krauss does not plan to discuss unlabeled/investigational uses of a commercial product.
Dr. Milligan: disclosed no relevant financial relationships.
Dr. Montouris: scientific advisory board: Eisai Inc., Lundbeck; pregnancy registry expert panel: UCB, Inc. Dr. Montouris does not plan to discuss unlabeled/investigational uses of a commercial product.
Dr. Sirven: consultant: Acorda Therapeutics, Inc, NeuroPace, Inc., UCB, Inc. Dr. Sirven does not plan to discuss unlabeled/investigational uses of a commercial product.
Dr. Smith: disclosed no relevant financial relationships.
Kristin Della Volpe, Scientific Director, Talem Health, LLC
Eric VanStone, Principal, Talem Health, LLC
Joanna Krause, MPH, Grants Manager, Boston University School of Medicine, CME
The members of the Planning Committee have no significant relationships to disclose.
This activity is supported by an educational grant from Eisai Inc.
For questions regarding this CME activity, please contact Marilyn Morrow by phone, 800-913-9370 ext 2, or email, email@example.com.
4 Research Drive, Suite 402
Shelton, CT 06484